NICE technology appraisal TA875 (semaglutide 2.4 mg, Wegovy) recommends semaglutide as an option for managing overweight and obesity in adults when all of the following criteria are met: [2] [3] BMI of at least 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease), or a BMI of 3034.9 kg/m in specific circumstances defined within the appraisal (for example, recent-onset type 2 diabetes) Treatment is delivered as part of a specialist multidisciplinary weight management service (Tier 3 or equivalent) Use is recommended for a maximum of two years under current NHS commissioning arrangements NICE technology appraisal TA1026 addresses tirzepatide (Mounjaro) for weight management, recommending it for adults with a BMI of 35 kg/m or above alongside at least one weight-related comorbidity, again within a specialist service context
The plasma stability of GLP-1MK-801 was optimized through incorporation of different cysteine homologues to the C terminus of the peptide to facilitate disulfide conjugation to the linker (Extended Data Fig
So, you can say the FDA wont take any responsibility for compounded drugs' safety, quality, or effectiveness
Body weight reduction was a secondary endpoint in clinical trials
therefore, the log-normal distribution was adopted
Can I still use the medication if it was left out of the fridge overnight
